"Pseudomonas aeruginosa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection.
| Descriptor ID |
D011550
|
| MeSH Number(s) |
B03.440.400.425.625.625.100 B03.660.250.580.590.050
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pseudomonas aeruginosa".
Below are MeSH descriptors whose meaning is more specific than "Pseudomonas aeruginosa".
This graph shows the total number of publications written about "Pseudomonas aeruginosa" by people in this website by year, and whether "Pseudomonas aeruginosa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 3 | 4 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 3 | 0 | 3 |
| 2001 | 1 | 1 | 2 |
| 2002 | 5 | 0 | 5 |
| 2003 | 6 | 3 | 9 |
| 2004 | 5 | 2 | 7 |
| 2005 | 9 | 5 | 14 |
| 2006 | 4 | 4 | 8 |
| 2007 | 5 | 0 | 5 |
| 2008 | 5 | 3 | 8 |
| 2009 | 2 | 3 | 5 |
| 2010 | 5 | 2 | 7 |
| 2011 | 5 | 4 | 9 |
| 2012 | 4 | 1 | 5 |
| 2013 | 2 | 6 | 8 |
| 2014 | 3 | 1 | 4 |
| 2015 | 1 | 2 | 3 |
| 2016 | 0 | 3 | 3 |
| 2017 | 6 | 2 | 8 |
| 2018 | 2 | 0 | 2 |
| 2019 | 4 | 3 | 7 |
| 2020 | 4 | 1 | 5 |
| 2021 | 4 | 3 | 7 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 5 | 5 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pseudomonas aeruginosa" by people in Profiles.
-
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin. Antimicrob Agents Chemother. 2024 Aug 07; 68(8):e0012724.
-
Impact of Pseudomonas aeruginosa on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis. J Med Econ. 2024 Jan-Dec; 27(1):671-677.
-
Development and validation of a rabbit model of Pseudomonas aeruginosa non-ventilated pneumonia for preclinical drug development. Front Cell Infect Microbiol. 2023; 13:1297281.
-
The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy. Antimicrob Agents Chemother. 2024 Jan 10; 68(1):e0100923.
-
Interlaboratory comparison of Pseudomonas aeruginosa phage susceptibility testing. J Clin Microbiol. 2023 12 19; 61(12):e0061423.
-
Class-Driven Synergy and Antagonism between a Pseudomonas Phage and Antibiotics. Infect Immun. 2023 08 16; 91(8):e0006523.
-
Characterization of wound microbes in epidermolysis bullosa: A focus on Pseudomonas aeruginosa. Pediatr Dermatol. 2023 Sep-Oct; 40(5):863-865.
-
The upper airway microbiome in Hispanic children with cystic fibrosis. Pediatr Pulmonol. 2023 Aug; 58(8):2298-2307.
-
In the Clear: Long-term pulmonary function benefits associated with Pseudomonas aeruginosa eradication. J Cyst Fibros. 2023 01; 22(1):7-8.
-
Filamentous bacteriophage delays healing of Pseudomonas-infected wounds. Cell Rep Med. 2022 06 21; 3(6):100656.